Product image of Myfortic (Mycophenolic Acid) supplied by GNH India

Myfortic

Active Ingredient:
Mycophenolic Acid
Origin:
EU

Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an enteric‑coated tablet for oral use. It works by inhibiting lymphocyte proliferation and is indicated for the prevention of organ rejection in renal, heart and liver transplant patients.

GNH India supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Novartis Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myfortic (mycophenolate sodium) is used in transplantation medicine to suppress immune‑mediated organ rejection.

  • Renal transplantation: helps prevent acute and chronic rejection of the transplanted kidney.
  • Heart transplantation: reduces risk of graft rejection and supports long‑term graft survival.
  • Liver transplantation: aids in preventing rejection of the transplanted liver and maintaining graft function.

How It Works

  • Mycophenolic acid, released from mycophenolate sodium, selectively inhibits inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanosine nucleotides. By depleting guanosine pools, it blocks proliferation of T‑ and B‑lymphocytes, which rely on this pathway for clonal expansion, thereby attenuating the immune response that leads to organ graft rejection.

Side Effects

Myfortic may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.
  • Hematologic changes: anemia, leukopenia, or thrombocytopenia.
  • Headache: mild to moderate headache episodes.
  • Elevated liver enzymes: mild transaminase elevations.

Serious or Rare Side Effects

  • Severe infection: opportunistic infections such as CMV or PCP.
  • Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.
  • Nephrotoxicity: worsening renal function.
  • Malignancy: increased risk of post‑transplant lymphoproliferative disorder.
  • Life‑threatening hypersensitivity: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

When prescribing Myfortic, clinicians should consider several safety and handling precautions.

  • Monitor blood counts: regular CBC to detect leukopenia or anemia.
  • Assess renal function: adjust therapy if creatinine rises.
  • Evaluate liver enzymes: periodic LFTs for hepatotoxicity.
  • Infection vigilance: screen for latent infections and vaccinate appropriately.
  • Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Avoid Interactions

Myfortic can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Antimetabolites (e.g., azathioprine): additive bone‑marrow suppression.
  • Live vaccines: increased risk of severe infection.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolate exposure.

Moderate Interactions (Monitor Closely)

  • Antacids or proton pump inhibitors: may affect absorption of the enteric‑coated tablet.
  • ACE inhibitors or ARBs: combined use may increase risk of renal impairment.
  • Non‑live vaccines: monitor immune response.

Frequently Asked Questions

Myfortic is prescribed to prevent rejection of transplanted organs. It is approved for use in patients who have received kidney, heart, or liver transplants, helping to maintain graft function by suppressing the immune response that can damage the new organ.

Mycophenolic acid, the active component of Myfortic, blocks the enzyme inosine monophosphate dehydrogenase. This inhibition reduces the synthesis of guanosine nucleotides, which are essential for the proliferation of T‑ and B‑lymphocytes, thereby dampening the immune system’s ability to attack a transplanted organ.

The dosage of Myfortic is individualized by the prescribing clinician based on the patient’s transplant type, renal function, and other clinical factors. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Safety data for Myfortic in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs the possible risk to the fetus or infant, and this decision must be made by a specialist in transplant medicine.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolate sodium) is an antimetabolite that specifically inhibits lymphocyte proliferation, whereas calcineurin inhibitors such as tacrolimus act on T‑cell activation pathways. Myfortic is often used in combination with other agents to achieve synergistic immunosuppression while offering a different side‑effect profile.

Myfortic tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Myfortic is taken orally as an enteric‑coated tablet. The tablet should be swallowed whole with water, typically twice daily, unless the prescribing physician advises a different schedule based on the patient’s therapeutic plan.

Serious risks include opportunistic infections, progressive multifocal leukoencephalopathy (PML), severe hematologic abnormalities, and rare but life‑threatening hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection or blood‑cell abnormalities.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolate sodium or any of its excipients. It should also be avoided in individuals with uncontrolled severe infections or those receiving live vaccines without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT